TRIM33 and cancer: Next, they performed mass spectrometry sequencing on the immunoprecipitates from five of the anti–TIF1-γ–positive patients without cancer and identified 23 candidate autoantigens, subsequently validating 10 of these targets that were unique to DM patients as compared with healthy controls (6).